Literature DB >> 3978106

Action of phospholipase A2 on bilayers. Effect of inhibitors.

M K Jain, D V Jahagirdar.   

Abstract

Action of several solutes on the kinetics of phospholipase-A2-catalyzed hydrolysis of the ternary codispersions containing dimyristoylphosphatidylcholine + 1-palmitoyllysophosphatidylcholine + palmitic acid is examined. The kinetics of hydrolysis is interpreted in terms of the ability of the enzyme to bind to the substrate interface. The inhibitory effect of these solutes is correlated with their ability to modify fluorescence intensity of the bound enzyme, to modify the phase-transition profile, and to inhibit aggregation/fusion of the ternary codispersions. Based on these observations, it is suggested that the solutes like n-alkanols, ketamine, alphadolone, alphaxalone, flufenamic acid, tobramycin, mepacrine, EMD 21657 and U-10029A modulate the phase equilibria in the codispersions and thus noncompetitively inhibit the phospholipase action. Inhibition by feverfew extract (Tanacetum parthemium) is also by a similar mechanism. Lipid-soluble drugs as indomethacin had little effect on the kinetics of hydrolysis. All these inhibitors decrease the total extent of hydrolysis of the available substrate. However, none of these inhibitors have any effect on the hydrolysis of monomeric substrate or on the inactivation of the phospholipase A2 by p-bromophenacylbromide. These observations suggest that all these inhibitors do not interact directly with the catalytic site of the free or the bound enzyme, and their effect is primarily on the enzyme-binding sites on the substrate vesicle, that is, by perturbation of lipid-protein interaction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3978106     DOI: 10.1016/0005-2736(85)90451-1

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  10 in total

1.  Competitive inhibition of phospholipase A2 in vesicles.

Authors:  M K Jain; W Yuan; M H Gelb
Journal:  Biochemistry       Date:  1989-05-16       Impact factor: 3.162

2.  Effects of dipalmitoylglycerol and fatty acids on membrane structure and protein kinase C activity.

Authors:  E M Goldberg; R Zidovetzki
Journal:  Biophys J       Date:  1997-11       Impact factor: 4.033

3.  The electrostatic basis for the interfacial binding of secretory phospholipases A2.

Authors:  D L Scott; A M Mandel; P B Sigler; B Honig
Journal:  Biophys J       Date:  1994-08       Impact factor: 4.033

4.  Effects of diacylglycerols and Ca2+ on structure of phosphatidylcholine/phosphatidylserine bilayers.

Authors:  E M Goldberg; D S Lester; D B Borchardt; R Zidovetzki
Journal:  Biophys J       Date:  1994-02       Impact factor: 4.033

5.  Late preventive effects of quinacrine on carbon tetrachloride induced liver necrosis.

Authors:  A González Padrón; E G de Toranzo; J A Castro
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

6.  Effects of chlorpromazine on the enzymatic and toxic properties of the most basic phospholipase A2 from Vipera russelli snake venom.

Authors:  A S Babu; T V Gowda
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

7.  Potential therapeutic efficacy of inhibitors of human phospholipase A2 in septic shock.

Authors:  P Vadas; E Stefanski; W Pruzanski
Journal:  Agents Actions       Date:  1986-11

8.  Effects of diacylglycerols on conformation of phosphatidylcholine headgroups in phosphatidylcholine/phosphatidylserine bilayers.

Authors:  E M Goldberg; D S Lester; D B Borchardt; R Zidovetzki
Journal:  Biophys J       Date:  1995-09       Impact factor: 4.033

9.  A requirement for membrane-associated phospholipase A2 in platelet cytotoxicity activated by receptors for immunoglobulin G and complement.

Authors:  D E Symer; W A Paznekas; H S Shin
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

10.  Assay of phospholipases A(2) and their inhibitors by kinetic analysis in the scooting mode.

Authors:  M K Jain; B Z Yu; M H Gelb; O G Berg
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.